Video Interview: TLC Delivers Sustained Release And Improved Tissue Targeting

Ensuring difficult-to-deliver drugs get to target sites is a common challenge for many pharma and biotech companies. George Yeh, president of Taiwan Liposome Co, tells Mike Ward, global director of content for Informa's pharma insights portfolio, how his company is developing more effective treatments for oncologic and ophthalmologic diseases and for pain using proprietary technology that provides sustained release and improved tissue targeting. He explains how the company's offering, which is underpinned by lipid-based formulation and scale-up for parenteral drugs using micelles and nanoparticles, helps optimize the pharmacokinetics of drugs for better efficacy and lower toxicity, and thus prolong the product lifecycle of branded drugs. Specifically, he explains how approved, commercialized drugs and major partners validate TLC's lipid-based nano-delivery technology and its ability to bring difficult-to-manufacture, difficult-to-scale-up products to market.

Ensuring difficult-to-deliver drugs get to target sites is a common challenge for many pharma and biotech companies. George Yeh, president of Taiwan Liposome Co, tells Mike Ward, global director of content for Informa's pharma insights portfolio, how his company is developing more effective treatments for oncologic and ophthalmologic diseases and for pain using proprietary technology that provides sustained release and improved tissue targeting. He explains how the company's offering, which is underpinned by lipid-based formulation and scale-up for parenteral drugs using micelles and nanoparticles, helps optimize the pharmacokinetics of drugs for better efficacy and lower toxicity, and thus prolong the product lifecycle of branded drugs. Specifically, he explains how approved, commercialized drugs and major partners validate TLC's lipid-based nano-delivery technology and its ability to bring difficult-to-manufacture, difficult-to-scale-up products to market.

This interview took place during EBD Group's Biotech Showcase in San Francisco, Jan. 11-13, 2016

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurological

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By 

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.